PD-1-CD28 fusion proteins and their use in medicine
US11192935B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Jun 20, 2016 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Sep 2, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/03
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to PD-1-CD28 fusion proteins, nucleic acid molecules, vectors, transduced cells carrying nucleic acid molecules or vectors of the present invention or expressing the fusion proteins of the present invention, methods and kits comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention. The invention also provides the use of said transduced cells in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said transduced cells expressing the fusion proteins of the present invention for use in a method of treating of diseases, in particular in the medical intervention of diseases characterized by PD-L1 and/or PD-L2 expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.